LEO Pharma buys US biotech Replay for 50 million dollars
The Danish drugmaker will pay 50 million dollars upfront for the gene therapy firm. The deal adds rare skin disease treatments as LEO prepares for an IPO.
LEO Pharma will acquire United States drug developer Replay for $50M upfront to expand its rare skin disease portfolio. The deal includes undisclosed milestone payments and royalties for Replay's preclinical gene therapy platform. The acquisition signals LEO Pharma's pivot toward high-value genomic treatments as it prepares for a potential IPO.
### The Gene Therapy Pivot LEO Pharma CEO Christophe Bourdon said the purchase adds an experimental gel-based gene therapy to the company's dermatology pipeline. Replay uses a modified herpes virus to deliver genetic material into skin cells, targeting conditions like dystrophic epidermolysis bullosa.
